Supplementary Figure 9 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Genomic characterization of NSCLC cases harboring oncogenic / likely oncogenic MET TKD mutations in cohort #2. (A) Oncoprint summarizing the genomic profile and (B) the TMB value of the 78 NSCLC cases with oncogenic / likely oncogenic MET TKD mutations without other concurrent driver alterations according to NCCN guidelines. (C) Comparison of the genomic profile of NSCLC cases with oncogenic / likely oncogenic MET TKD mutations (N=78) and METex14-altered NSCLC (N=2036)